Pfizer Inc. (PFE) — closed signal from December 6, 2025
Partial Published before the outcome was known, scored automatically when the window closed on March 6, 2026.
Predicted vs. what happened
What happened
Reached 56% of the predicted growth at its peak, without hitting the target.
The thesis — published December 6, 2025
Pfizer looks like a value and income pick in big pharma. A valuation model suggests the stock could be worth about $62, meaning current prices look cheap because investors worry about replacing COVID-related sales and handling acquisitions. Market mood is improving and buying has picked up, so we expect modest gains in months ahead. Still, results from drug trials and how management spends cash could limit upside, so we prefer buying on small dips rather than a full conviction buy.
Primary drivers
- Investors are less worried about COVID revenue and sentiment is improving.
- Valuation work points to roughly $62 fair value, implying meaningful upside.
- Many more buyers than usual suggest renewed interest in the stock.
- Future trial results and cost control will decide if the rerating lasts.
How it played out
PFE: thesis only partly played out
Lyra published PFE at $26.03 on 2025-12-06, with expected growth of 13%. The thesis pointed to value and income appeal in big pharma, a valuation view around $62, improving sentiment, stronger buying interest, and the risk that trial results and cash use could limit upside.
Inside the window, PFE rose but did not reach the $29.41 target. It peaked at $27.94 on 2026-02-11, a 7.3% gain, then ended the window at $27.05 on 2026-03-06. The thesis partly played out. The stock moved in the expected direction, but it never got to the target.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.